Funding will accelerate commercialization and US lumbar trial for the iFACTOR Peptide Enhanced Bone Graft, a unique drug-device technology enhances the body's natural bone healing process through cellular activity that is directional and predictable.
The i(FACTOR Peptide Enhanced Bone Graft is based on proprietary biomimetic small peptide technology that has a novel mechanism of action (attract, attach, and activate) that induces osteoblast cell proliferation and differentiation to accelerate new bone formation in patients with degenerative disc disease.
Cerapedics received Premarket Approval from the US FDA for the use of i-FACTOR Peptide Enhanced Bone Graft in anterior cervical discectomy and fusion procedures. The company has also initiated an IDE clinical trial in transforaminal lumbar interbody fusion surgery.
Privately held Cerapedics is focused on developing and commercializing its proprietary synthetic small peptide technology platform.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT